<DOC>
	<DOCNO>NCT00240942</DOCNO>
	<brief_summary>Endometriosis condition abnormal growth tissue histologically resemble line uterus ( endometrium ) present outside uterus . This study investigate effect daily dose letrozole compare GnRH safe addition effective reduce measurable endometriosis lesion reduce pain patient active endometriosis pretreated GnRH analog 2 month .</brief_summary>
	<brief_title>Letrozole Treatment Severe Recurrent Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion Criteria Premenopausal woman &gt; 18 year age . Laparoscopic Histologically confirm diagnosis moderate severe endometriosis accord rASRMScore III IV BMI le 40 kg/mÂ² . Patient sexually abstinent use mechanical ( condom , diaphragm ) sterilization method contraception willing continue use throughout study . Patient willing able comply study requirement . Written informed consent . Exclusion Criteria Endometriosis stage III acc . accord rASRM Women cause chronic pelvic pain include infectious , gastrointestinal , musculoskeletal , neurologic psychiatric . Significant abnormality physical laboratory examination include renal liver function twice normal range . Patient desire pregnancy duration study , pregnant breast feeding . GnRH therapy last 6 month Use hormonal contraception , selective estrogen receptor modulators , progestin , estrogen , steroid , ovulation induction 4 week prior inclusion study . Untreated abnormal pap smear gynecologic condition . History venous thrombosis event include deep vein thrombosis , pulmonary embolism , retinal vein thrombosis . History stroke , complicate migraine , document transient ischemic attack . Known hypersensitivity ingredient study medication . Treatment aromatase inhibitor Other investigational drug within past 30 day concomitant use investigational drug . History noncompliance medical regimen , patient consider potentially unreliable . Additional protocoldefined inclusion / exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>GnRH analog</keyword>
	<keyword>Aromataseinhibitor</keyword>
	<keyword>Letrozole</keyword>
</DOC>